ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.
ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.
ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.
ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.
Phase 3 study data with bempedoic acid show 28% additional LDL-c lowering on background therapy and 33% reduction of hsCRP in patients with atherosclerotic CVD or at high risk for ASCVD.
A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.
12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.
A genetic predisposition to higher childhood BMI was associated with an increased risk of type 2 diabetes, coronary artery disease, and cardio-metabolic traits in adult life.
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab
In a single-center observational study, less than 50% of acute coronary syndrome patients were on recommended therapies at discharge, which was associated with an increase in 1-year mortality.
Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.
Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.